The co-treatment of rosuvastatin with dapagliflozin synergistically inhibited apoptosis via activating the PI3K/AKt/mTOR signaling pathway in myocardial ischemia/reperfusion injury rats

The co-treatment of rosuvastatin with dapagliflozin synergistically inhibited apoptosis via activating the PI3K/AKt/mTOR signaling pathway in myocardial ischemia/reperfusion injury rats

The purpose of the present study was to evaluate the role of co-treatment of rosuvastatin (RSV) and dapagliflozin (DGZ) preconditioning in myocardium ischemia/reperfusion (I/R) injury and to further investigate the underlying mechanism.

Bibliographic Details
Main Authors: Gong Lei, Wang Xuyang, Pan Jinyu, Zhang Mingjun, Liu Dian, Liu Ming, Li Li, An Fengshuang
Format: Article
Language:English
Published: De Gruyter 2020-12-01
Series:Open Medicine
Subjects:
rosuvastatin
dapagliflozin
apoptosis
pi3k/akt/mtor
ischemia/reperfusion
Online Access:https://doi.org/10.1515/med-2021-0005

Internet

https://doi.org/10.1515/med-2021-0005

Similar Items